Insulinas Farm Aplic UNLP

Uso Racional de las Insulinas

Fisiología de la Insulina

• La liberación de insulina se activa por la entrada de glucosa en las células beta, alterando las concentraciones de ATP y ADP, lo que bloquea los canales de potasio y provoca despolarización celular. Esto permite la entrada de calcio, crucial para la liberación de insulina.

Mecanismo de Acción

• La insulina actúa sobre receptores específicos unidos a tirosina, requiriendo dos moléculas para su activación. Una vez activado, el receptor inicia eventos como la expresión de GLUT4 en membranas celulares, facilitando el ingreso de glucosa.

Clasificación y Tipos de Insulina

• Las insulinas se clasifican en estándar (clásicas) y análogos (modificadas). Todas son producidas mediante ADN recombinante en bacterias como Escherichia coli. Los análogos presentan diferencias significativas en farmacocinética pero estimulan el mismo receptor.

Características Farmacológicas

• La insulina regular (cristalina) tiene un inicio rápido (30-60 min), efecto máximo a 2-3 horas y duración aproximada de 6 horas. En contraste, la insulina NPH es más lenta con un inicio entre 2-4 horas y duración que puede llegar hasta 24 horas dependiendo del paciente.

Análogos Ultra Rápidos

• Los análogos ultra rápidos como lispro, aspart e inhalados tienen un inicio muy rápido (5-15 minutos) y efectos máximos entre media hora a una hora y media. Sin embargo, requieren inyecciones adicionales para acción lenta debido a problemas respiratorios asociados con insulinas inhaladas.

Indicaciones Clínicas para Insulinoterapia

• Se recomienda insulinoterapia en todos los pacientes con diabetes tipo 1; también se utiliza en diabetes tipo 2 cuando hay hiperglucemias sintomáticas o hemoglobina glicosilada mayor a 10%. Puede ser necesaria durante emergencias o complicaciones asociadas a otras comorbilidades.

Insulin Therapy: Approaches and Insights

Overview of Insulin Administration

• Insulin therapy can be intensified with multiple injections or insulin pumps, while conventional methods involve one or two daily injections combined with oral antidiabetic medications, specifically for Type 2 diabetes.

• Conventional insulin therapy is typically initiated in Type 1 diabetes when there is still some pancreatic insulin suppression; it may be challenging for patients who refuse intensive therapy.

Flexibility and Limitations of Treatment

• The conventional treatment method offers simplicity but lacks flexibility, as adjustments are limited to meal timing and physical activity.

• Intensive insulin therapy aims to mimic physiological insulin release, requiring patient training for continuous self-monitoring and decision-making based on glycemic control.

Advantages and Challenges of Intensive Therapy

• Intensive therapy is more flexible and has been shown to reduce microvascular complications; however, it demands significant time investment from patients, families, and healthcare teams.

• Modern devices like pen injectors have replaced syringes due to ease of use and reduced trauma from needles.

Devices Used in Insulin Delivery

• Insulin pumps deliver medication subcutaneously every three days using a reservoir system; proper needle usage is crucial to avoid injuries from reused needles.

Mechanisms of Action in Different Insulins

• Standard insulins function similarly to endogenous insulin; absorption kinetics vary between regular (rapid action) and NPH (slow action), the latter being modified with protein molecules for slower release.

Clinical Evidence on Glycemic Control

• Studies indicate that effective glycemic control significantly reduces long-term complications. For instance, a decrease in HbA1c by 1% correlates with a reduction in microvascular complications by up to 25%.

Longitudinal Studies on Diabetes Management

• The DCCT study demonstrated that intensive glucose control prevents chronic complications such as retinopathy and nephropathy over ten years.

• Following the initial study period, participants were monitored for an additional twenty years to assess the long-term effects of intensive treatment on chronic complication prevention.

This structured overview provides insights into various aspects of insulin therapy, highlighting its complexities while emphasizing the importance of tailored approaches based on individual patient needs.

Study of Intensive Treatment in Diabetes Patients

Overview of Patient Follow-Up

• The study followed 1,440 initial patients, with 1,375 continuing after seven years, demonstrating the effectiveness of intensive treatment.

• After conventional treatment, 83% transitioned to intensive therapy involving multiple insulin directions; evaluations continued for 20 years.

Long-Term Effects of Intensive Treatment

• Patients on intensive treatment maintained some benefits even with less rigorous follow-up, showcasing a "memory effect" where early good control led to fewer complications later.

• Benefits were observed not only in microvascular complications (retina, kidney, nerves) but also in macrovascular events due to better metabolic control.

Insights from Key Studies

• The Kumamoto Study highlighted that intensive insulin therapy reduced microvascular complications in Type 2 diabetes patients; however, its applicability across different populations is debated due to genetic differences.

• There is insufficient evidence supporting monotherapy with insulin for Type 2 diabetes; combination therapies may be more effective.

Comparative Studies and Recommendations

• Research comparing insulin with metformin and sulfonylureas in gestational diabetes showed similar adverse effects; hypoglycemia risk increases with tighter glucose control.

• It’s recommended that diabetic patients maintain blood glucose levels above 80 mg/dL to minimize risks associated with low blood sugar.

Adverse Effects and Management Strategies

• Insulin administration can lead to weight gain (2–4 kg), prompting caution in obese patients unless they have Type 1 diabetes.

• Historical allergic reactions were more common with non-human insulins; lipodystrophy issues are prevalent among these older formulations.

Pharmacokinetics of Insulin Analogues

• Rapid-action analogues differ from crystalline insulins by being absorbed faster (5–15 minutes), which allows for flexible administration around meals compared to regular insulins requiring pre-meal timing.

• Despite pharmacokinetic differences between rapid-action analogues and standard insulins, efficacy remains similar across both types for managing diabetes.

Clinical Implications and Future Directions

• Current studies show no significant difference in severe hypoglycemia rates between rapid-action analogues and traditional insulins while offering greater convenience for meal timing.

• Further research is needed on whether rapid-action analogues can alter the development of microvascular complications compared to standard insulins.

Nutrition and Insulin Management in Diabetes

Importance of Routine in Nutrition

• Patients often express that having a consistent routine with their diet is crucial for comfort and adherence to treatment, as indicated by quality of life surveys.

Rapid-Acting Insulin Analogues

• Rapid-acting insulin analogues offer discrete advantages, including similar efficacy to regular human insulin in reducing HbA1c levels and a lower incidence of severe hypoglycemia, making them preferable for patients prone to such episodes.

• Despite their benefits, rapid-acting insulins are more expensive than regular insulin and lack extensive long-term data on efficacy for preventing microvascular and macrovascular complications.

Long-Acting Insulin Analogues

• Long-acting insulins like glargine are absorbed more slowly compared to NPH insulin, allowing for once-daily administration versus the potential need for twice-daily dosing with NPH.

• In Type 1 diabetes, there are no significant differences in HbA1c levels between patients using glargine or NPH; similar findings apply to Type 2 diabetes patients who also take oral antidiabetic medications.

Adverse Effects of Insulin Analogues

• One advantage of long-acting insulins is a reduced incidence of nocturnal hypoglycemia due to their stable kinetics. However, they may lead to slight weight gain (0.5 - 2 kg).

• Glargine has been associated with injection site pain and lipoatrophy/lipohypertrophy at higher rates than NPH. There are also concerns about its safety regarding cancer risk based on observational studies.

Safety Concerns with Glargine

• The mechanism by which insulin stimulates nuclear activity could potentially alter cellular growth patterns, raising concerns about cancer risks among certain patient populations.

Administration Guidelines for Glargine

• Glargine should be administered once daily without mixing it with other insulins due to potential precipitation issues; only regular and NPH can be mixed safely.

Newer Long-Acting Insulin: Degludec

• Degludec is noted as a newer long-lasting insulin analogue that allows flexible dosing schedules but still requires maintaining a consistent daily routine.

Cardiovascular Safety Studies

• Initial reports raised cardiovascular risk concerns regarding degludec; comparative studies have since shown no significant difference in cardiovascular events between degludec and glargine users over 30 months.

Comparative Mortality Studies

• A retrospective study involving 128,000 Type 2 diabetes patients found similar rates of cardiovascular events and overall mortality between users of human insulin and those using analogues like glargine.

This structured summary provides an overview of key discussions surrounding nutrition management and various types of insulin used in diabetes care while highlighting important insights from the transcript.

Adherence to Treatment and Insulin Management

Importance of Treatment Adherence

• Emphasizes the significance of adherence to treatment in avoiding forgetfulness and mistakes. A key advantage is that dosage adjustments are made only once a week, based on blood glucose levels from the previous two or three days.

• Once patients stabilize their blood glucose and insulin levels with degludec, there is often a decrease in the need for rapid-acting insulin.

Efficacy of Rapid-Acting Insulin Analogues

• Summarizes that rapid-acting insulin analogues have similar efficacy to traditional insulin in reducing glycosylated hemoglobin (HbA1c).

• For patients requiring administration twice daily, glargine and degludec can be administered just once daily, which may lead to fewer nocturnal hypoglycemic incidents.

Considerations for Patients with Frequent Hypoglycemia

• Highlights that glargine and degludec are considered alternatives for patients experiencing frequent hypoglycemia due to their lower incidence rates.

• Notes the higher cost associated with these insulins and mentions a lack of long-term efficacy data regarding microvascular complications and safety concerns.